The role of androgen deprivation therapy (ADT) in combination with radiotherapy (RT) in intermediate-risk prostate cancer (IRPC) remains controversial, particularly in patients receiving dose-escalated RT (DERT).
There is a high demand for bladder sparing therapies in patients who do not respond to bacillus Calmette-Guérin (BCG). To report the mid-term results of intravesical gemcitabine in non-muscle-invasive bladder cancer (NMIBC) patients, who failed BCG and who were unwilling to undergo radical cystectomy (RC).
The field of research in bladder cancer has seen significant advances in recent years. Next-generation sequencing has identified the genes most mutated in bladder cancer. This wealth of information allowed the definition of driver mutations, and identification of actionable therapeutic targets, as well as a clearer picture of patient prognosis and therapeutic direction.
Muscle-invasive bladder cancer (MIBC) frequently harbors mutations in the CDKN1A gene, which encodes the tumor suppressor protein p21, with the majority of alterations truncating the peptide. The effect of these mutations is poorly understood.
Financial toxicity (FT) has been defined as the patient-level impact of the costs of cancer care. Our objective was to better characterize FT among bladder cancer patients as well as oncologic, demographic and insurance characteristics related to FT.
(UroToday.com) Immunotherapeutic approaches have gained an increasingly large role in the treatment of many cancers. In urologic oncology, there is a large role in the first-line management of patients with metastatic renal cell carcinoma, in Bacillus Calmette-Guerin (BCG)-refractory non-muscle invasive bladder cancer, and in advanced bladder cancer. In addition to monotherapy, immunotherapy is increasingly being utilized […]
Charles Ryan: Hello everybody. We have exciting news in the area of prostate cancer. There has just been an FDA approval of Gallium-68 PSMA PET scans for prostate cancer. And I’m joined by two experts in nuclear medicine, Phil Koo from Banner MD Anderson in Phoenix, Arizona, and Tom Hope from the University Of California, […]
(UroToday.com) Dr. Kelly Stratton gave a presentation at the 2020 Society of Urologic Oncology (SUO) Annual Virtual Meeting on peri-operative therapy for muscle-invasive bladder cancer (MIBC). He began his talk by demonstrating that the outcomes after radical cystectomy differ significantly according to the pathological results of cystectomy (Figure 1).1 Due to the fact that in some patients, […]
(UroToday.com) During the 2020 Society of Urologic Oncology (SUO) annual meeting, Dr. Neema Navai presented on the management of “node only” metastatic bladder cancer, debating for the use of surgery following chemotherapy. The mechanism for metastatic disease is not entirely understood yet. There are several potential possibilities, which include:
(UroToday.com) Current serum tumor markers for testicular germ cell tumor are limited by low sensitivity, with several drawbacks, including, (ii) low expression in seminoma, embryonal carcinoma, and teratoma and (ii) ~50% sensitivity. Taken together, pre-orchiectomy serum tumor markers are not ideal to diagnose malignant disease. However, there is growing evidence supporting the use of circulating miR-371a-3p […]
